The FINANCIAL -- NIB and the Swedish medical equipment solutions provider Elekta AB have signed a five-year loan agreement of GBP 90 million (EUR 104 million) to finance R&D costs for the development of new radiotherapy solutions.
Elekta’s research programme for 2016–2020 focuses on the development of new equipment and software for the treatment of cancers and brain disorders by means of radiotherapy.
This includes the advancement of technology for improved quality of diagnostic images of tumours and a more precise targeting of cancerous tissue during radiation therapy, according to NIB.
Electa’s R&D programme is expected to change the current standard of care for cancer patients by improving the precision of treatment delivery.
“The research conducted by Elekta in Sweden and Finland will support medical advances into new radiotherapy treatment options. Further, the investment will help Elekta to maintain its leading market position”, says Henrik Normann, NIB President & CEO.
"NIB’s loan provides long-term financing for the implementation of our R&D programme, and contributes to the diversification of our funding sources. We appreciate that NIB has ensured a time-efficient and flexible execution of the loan process”, says Håkan Bergström, CFO, Elekta.
Elekta operates several research centres worldwide, including in Sweden and Finland.
Elekta AB develops clinical solutions and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as medical software solutions. Elekta is headquartered in Stockholm, Sweden, and employs around 3,600 people globally.